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Background-—Right bundle branch block is an established predictor for new conduction disturbances and need for a permanent
pacemaker (PPM) after transcatheter aortic valve replacement. The aim of the study was to evaluate the absolute rates of
transcatheter aortic valve replacement related PPM implantations in patients with pre-existent right bundle branch block and
categorize for different transcatheter heart valves.
Methods and Results-—We pooled data on 306 transcatheter aortic valve replacement patients from 4 high-volume centers in
Europe and selected those with right bundle branch block at baseline without a previously implanted PPM. Logistic regression was
used to evaluate whether PPM rate differed among transcatheter heart valves after adjustment for confounders. Mean age was
837 years and 63% were male. Median Society of Thoracic Surgeons score was 6.3 (interquartile range, 4.1–10.2). The following
transcatheter valve designs were used: Medtronic CoreValve (n=130; Medtronic, Minneapolis, MN); Edwards Sapien XT (ES-XT;
n=124) and Edwards Sapien 3 (ES-3; n=32; Edwards Lifesciences, Irvine, CA); and Boston Scientiﬁc Lotus (n=20; Boston Scientiﬁc
Corporation, Marlborough, MA). Overall permanent pacemaker implantation rate post-transcatheter aortic valve replacement was
41%, and per valve design: 75% with Lotus, 46% with CoreValve, 32% with ES-XT, and 34% with ES-3. The indication for PPM
implantation was total atrioventricular block in 98% of the cases. Lotus was associated with a higher PPM rate than all other valves.
PPM rate did not differ between ES-XT and ES-3. Ventricular paced rhythm at 30-day and 1-year follow-up was present in 81% at
89%, respectively.
Conclusions-—Right bundle branch block at baseline is associated with a high incidence of PPM implantation for all transcatheter
heart valves. PPM rate was highest for Lotus and lowest for ES-XT and ES-3. Pacemaker dependency remained high during follow-
up. ( J Am Heart Assoc. 2017;6:e005028. DOI: 10.1161/JAHA.116.005028.)
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P atients with severe aortic stenosis and a higher operativerisk for mortality are good candidates for transcatheter
aortic valve replacement (TAVR).1–4 TAVR involves placement
of a transcatheter heart valve (THV) that protrudes into the
left ventricular outﬂow tract. As such, the THV radial force
may impose on the adjacent conduction system and result in
conduction disturbances.5,6 Incidence of new left bundle
branch block (LBBB) and high-grade atrioventricular block (AV
block) varies according to patient demographics, anatomical
characteristics, and selected THV. New LBBB and permanent
pacemaker (PPM) implantation post-TAVR varies from 4% to
81% and from 0% to 49%, respectively, and is consistently
higher with the self-expanding CoreValve compared to
balloon-expandable Sapien valves.5,7,8
New THV designs have focussed on proﬁle reﬁnement,
paravalvular leak prevention, and the intrinsic feature of partial
or complete repositionability and retrievability,9–11 yet con-
duction disorders remain common. Right bundle branch block
(RBBB) at baseline is considered a dominant predictor for high-
degree AV block and PPM post-TAVR.7,12–16 Frequency of RBBB
at baseline in current TAVR practice ranges from 4% to 21%.7
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Knowledge of the respective PPM rates for different THV
designs in patients with RBBB may guide patient-tailored THV
selection. This multicenter collaboration sought to further
elucidate TAVR-related PPM rates in patients with pre-existent
RBBB and categorize for different THV designs.
Methods
Patient Selection
Between May 2008 and February 2016, 2845 patients under-
went TAVR in 4 tertiary care European institutions. All patients
were screened forRBBB (andabsenceof aPPM) before the TAVR
procedure and were included in a joint database collecting:
baseline demographics; TAVR procedure characteristics; new
conduction disorders within 24 hours; PPM at 30 days; and
electrocardiographic and clinical-follow-up data at 30 days and
1 year. THV selection was per institution’s discretion. A
minimum of 10 available cases per THV was a predeﬁned
requirement for further analysis, to secure solidity of data.
The 4 THVs used were CoreValve (Medtronic, Minneapolis,
MN), Sapien XT (ES-XT) and Sapien 3 (ES-3; Edwards
Lifesciences, Irvine, CA), and Lotus (Boston Scientiﬁc Corpo-
ration, Marlborough, MA). Figure 1 displays the patient ﬂow
diagram. All patients provided written informed consent for
the procedure and data analysis for research purposes per
institutional review board approval.
Outcomes
The primary outcome was implantation of a PPM within
30 days after the TAVR procedure. Secondary outcomes were
new-onset conduction disturbances within 24 hours: (1) third-
degree atrioventricular block (AV3B) and (2) alternating bundle
branch block (ie, change from RBBB to LBBB). The decision for
PPM was per treating physician’s discretion, but, in general, in
compliance with contemporary European Society of Cardiology
Guidelines on PPM.17 Clinical outcomes were reported using
the revised Valve Academic Research Consortium criteria.18
Statistical Analysis
Continuous variables are presented as meanSD or median
(interquartile range; IQR). Distribution of continuous variables
was assessed for normality with histograms and the Shapiro–
Wilk test. Continuous variables were compared using a Student
t test or Mann–Whitney U test, when applicable. Categorical
variables are expressed as percentages plus absolute numbers
and were tested with the chi-square test for trend.
Logistic regression was performed to identify predictors for
the primary outcome (ie, PPM). THVs were included in the
univariate analysis plus potential confounders in regard to the
primary outcome. The number of variables in the univariate
model was limited by the established rule of thumb of 10
events per variable.19 All selected variables were evaluated
using univariate logistic regression for inclusion in the
multivariate model, considering a P value of <0.20 as an
entry criterion. These variables remained in the multivariate
model, regardless of P value after adjustment. We controlled
for the interaction between valve type and alternative access,
because alternative access was seldom used with CoreValve
and Lotus. All statistical analyses were performed with SPSS
software (version 21.0.01; IBM Corp, Armonk, NY). A 2-sided
value of P<0.05 was considered statistically signiﬁcant.
Results
A total of 2845 consecutive patients underwent TAVR at 4
European centers. For the purpose of this study, 306 (11%)
Figure 1. Flow chart of study inclusion. ES-3 indicates Edwards
Sapien 3; ES-XT, Edwards Sapien XT; PPM, permanent pacemaker;
RBBB, right bundle branch block; THVs, transcatheter heart valves.
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patients with pre-existent RBBB (without a PPM in situ) were
extracted and further analyzed (Figure 1). Patient character-
istics are listed in Table 1. Mean age was 837 years, the
majority was male (194; 63%), and the median predicted risk
of mortality (Society of Thoracic Surgeons [STS] score) was
6.3% (IQR, 4.1–10.2). The CoreValve and Sapien-XT were used
in the majority of patients (42% and 41%, respectively). An
alternative access was used in 20% with the balloon
expandable ES-XT and ES-3 and 9% with CoreValve and not
with Lotus. Antiarrhythmic agents were commonly used; 13%
of patients used amiodarone and 4% digoxin.
Clinical Outcomes
All-cause mortality—within 48 hours following the
procedure—was 3% (n=10). Thirty-day mortality rate was 7%
(n=20) and 30-day stroke rate was 2% (n=5). One-year mortality
rate was 18% (n=44).
PPM Implantation
Conduction changes are summarized in Table 2. The primary
outcome—PPM implantation within 30 days—occurred in
41% of patients. The univariate analysis is summarized in
Table S1. The following variables were included in the
multivariate analysis: valve type; alternative access; body
mass index (BMI); sex; and an interaction term for valve
type9alternative access (because alternative access was not
applied with Lotus). Results from the multivariate analysis are
displayed in Figure 2. By multivariate analysis, PPM was more
common with Lotus than with the other THVs. Lotus was
associated with a signiﬁcantly higher PPM rate than all other
individual transcatheter heart valves (Lotus versus CoreValve:
odds ratio [OR], 3.69 [95% CI, 1.13–12.04]; P=0.030; Lotus
versus ES-XT: OR, 6.79 [95% CI, 2.05–22.52]; P=0.002; Lotus
versus ES-3: OR, 5.24 [95% CI, 1.30–21.25]; P=0.020). On the
contrary, PPM rate was lower with the ES-XT valve versus
CoreValve and Lotus (ES-XT vs CoreValve: OR, 0.54 [95% CI,
0.31–0.95]; P=0.033; ES-XT vs Lotus: OR, 0.15 [95% CI, 0.04–
0.49]; P=0.002). PPM rate between the balloon expandable
valves did not differ (ES-XT vs ES-3: OR, 0.91 [95% CI, 0.40–
2.07]; P=0.820). Another independent predictor for PPM in
the multivariable model was a higher BMI before TAVR
(multivariate OR, 1.08 per 1 kg/m2 increment [95% CI, 1.02–
1.14]; P=0.013). Alternative access was associated with a
lower rate of PPM in the univariate model (OR, 0.32 [95% CI,
Table 1. Patient Characteristics
CoreValve (N=130) ES-XT (N=124) Lotus (N=20) ES-3 (N=32) Overall (306) P Value
Age, meanSD 836 838 836 816 837 0.301
Male sex, n (%) 79 (61) 83 (67) 12 (60) 20 (63) 194 (63) 0.761
BMI in kg/m2, meanSD 265 274 297 274 275 0.319
Diabetes mellitus, n (%) 33 (25) 38 (31) 9 (45) 13 (41) 93 (30) 0.161
STS score in %, median [IQR] 6.5 [4.5–10.4] 7.0 [4.0–10.1] 5.9 [5.2–7.8] 4.5 [3.0–10.5] 6.3 [4.1–10.2] 0.186
PVD, n (%) 28 (22) 36 (29) 6 (30) 7 (22) 77 (22) 0.526
COPD, n (%) 41 (32) 40 (33) 5 (25) 7 (22) 93 (30) 0.634
Atrial fibrillation, n (%) 21 (16) 27 (22) 4 (20) 8 (25) 60 (20) 0.584
NYHA class ≥III, % (n) 101 (78) 103 (83) 14 (74) 17 (53) 235 (77) 0.005
History of stroke, n (%) 18 (14) 12 (10) 4 (20) 3 (9) 36 (12) 0.613
History of CABG, n (%) 15 (12) 19 (15) 5 (25) 10 (31) 49 (16) 0.033
History of PCI, n (%) 49 (38) 53 (43) 6 (30) 10 (31) 118 (39) 0.513
History of SAVR, n (%) 4 (3) 3 (2) 0 (0) 2 (6) 9 (3) 0.581
Digoxin use, n (%) 4 (3) 5 (4) 2 (13) 0 (0) 11 (4) 0.187
Amiodarone use, n (%) 18 (14) 16 (13) 2 (13) 2 (7) 38 (13) 0.792
Access, n (%)
Transfemoral 119 (91) 98 (79) 20 (100) 25 (78) 262 (86) 0.005
Transsubclavian 10 (8) 14 (11) 0 (0) 1 (3) 25 (8)
Transapical 1 (1) 12 (10) 0 (0) 6 (19) 19 (6)
Categorical variables are displayed as counts (percentages) and differences were tested using a chi-square test for trend. Continuous variables are displayed as meanSD or median [IQR]
and were tested with a Student t test or Mann–Whitney U test, depending on distribution. BMI indicates body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive
pulmonary disease; ES-3, Edwards Sapien 3; ES-XT, Edwards Sapien XT; IQR, interquartile range; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; PVD,
peripheral vascular disease; SAVR, surgical aortic valve replacement; STS, Society of Thoracic Surgeons.
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0.15–0.69]; P=0.004), but not in the multivariate model (OR,
0.26 [95% CI, 0.05–1.27]; P=0.095). There was an important
interaction between alternative access and valve type,
attributed to the fact that Lotus was not performed with
alternative access. The association between alternative
access and PPM was nonsigniﬁcant with any of the valve
types (CoreValve: OR, 0.234 [95% CI, 0.048–1.128]; P=0.070;
with ES-XT: OR, 0.565 [95% CI, 0.207–1.539]; P=0.264; with
ES-3: OR, 0.250 [95% CI, 0.0262–2.403]; P=0.230).
New-Onset Conduction Disturbances
Alternating bundle branch block within 24 hours was docu-
mented in 23 patients (8%). New-onset AV3B within 24 hours
was documented in 101 patients (36%). Univariate and
multivariate analysis addressing new AV3B are summarized
in Table S2. New AV3B was more common with Lotus than
with other individual THVs by multivariate analysis (Lotus vs
ES-XT: OR, 6.01 [95% CI, 1.93–18.67]; P=0.002; Lotus vs ES-
3: OR, 3.88 [95% CI, 1.02–14.82]; P=0.047; Lotus vs
CoreValve: OR, 3.80 [95% CI, 1.25–11.52]; P=0.018). New
AV3B was less common with the ES-XT valve than with Lotus
(OR, 0.17 [95% CI, 0.05–0.52]; P=0.002). New AV3B rate
between the balloon expandable valves was similar (ES-XT vs
ES-3: univariate OR, 0.59 [95% CI, 0.24–1.43]; P=0.240).
Of all patients with new AV3B within 24 hours of the TAVR
procedure, 91% received a PPM. One in 4 of these permanent
pacemakers were implanted more than 4 days after the TAVR
procedure. The documented indication for PPM implantation
was almost exclusively AV3B (98%). Follow-up electrocardio-
grams at 30 days and 1 year conﬁrmed ventricular pacing in
81% and 89%, respectively.
Discussion
The present study showed that tailored valve choice may
reduce rates of PPM implantations in patients with pre-
existent RBBB. Overall PPM rate post-TAVR in patients with
RBBB was 41% and was highest with Lotus (75%). More than
80% of patients with a PPM remained pacemaker dependent
at 30-day and 1-year follow-up.
Prevalence of RBBB in the general population ranges from
0.5% to 1.5%, has a male predominance, and increases with
age to 2.2% in patients above 55 years old.20,21 Prevalence of
pre-existent RBBB is 4% in patients undergoing surgical aortic
valve replacement (SAVR) with a mean age of 69 years22 and
is 10% in patients undergoing TAVR with a mean age of 81.7
RBBB is a dominant predictor for PPM after both TAVR and
SAVR.7,9,11,23,24 Not unexpectedly, patients with pre-existent
RBBB are more vulnerable for high-grade AV block given that
the conduction system is already impaired. With TAVR, the
radial force of a stented frame may impose pressure on the
conduction system embedded in the interventricular septum
within a couple of millimeters from the aortic annulus and may
further compromise the left bundle branch.14 Before patients
with RBBB evolve toward total AV block, an alternating bundle
branch can sometimes be recognized, as illustrated in
Figure 3. In our population, an alternating bundle branch
block within 24 hours post-TAVR could be detected in 8% of
patients.
According to a recent meta-analysis, TAVR with the self-
expanding CoreValve is associated with a higher PPM rate
compared with the balloon expandable ES-XT.7 PPM rate with
newer-generation THVs varies and deﬁnitely remains a clinical
issue, in particular with the mechanically expanded Lotus.
Table 2. Permanent Pacemaker Implantations and Conduction-Related Outcomes
CoreValve (N=130) ES-XT (N=124) Lotus (N=20) ES-3 (N=32) Overall (N=306) P Value
New AV3B <24 hours, n (%) 48 (39) 30 (27) 13 (68) 10 (39) 101 (36) 0.004
Alternating BBB <24 hours*, n (%) 10 (8) 7 (6) 3 (17) 3 (12) 23 (8) 0.457
New PPM, n (%) 60 (46) 40 (32) 15 (75) 11 (34) 126 (41) 0.001
Days to PPM, median [IQR] 2 [1–5] 3 [1–5] 1 [1–2] 2 [1–5] 2 [1–5] 0.546
Indication for PPM, n (%)†
AV3B 59 (98) 39 (97) 14 (93) 11 (100) 123 (98) 0.489
AV2B 1 (2) 0 (0) 1 (7) 0 (0) 2 (2)
Sick sinus syndrome 0 (0) 1 (3) 0 (0) 0 (0) 1 (1)
Ventricular paced rhythm at 30 days‡, n (%) 38 (81) 24 (92) 9 (69) 8 (73) 79 (81) 0.275
Ventricular paced rhythm at 1 year‡, n (%) 21 (91) 15 (94) 2 (67) 3 (75) 41 (89) 0.415
Categorical variables are displayed as counts (percentages) and differences were tested using a chi-square test for trend. Continuous variables are displayed as median [IQR] and were
tested with a Mann–Whitney U test. AV2B indicates second-degree atrioventricular block; AV3B, third-degree atrioventricular block; BBB, bundle branch block; ES-3, Edwards Sapien3; ES-
XT, Edwards Sapien XT; IQR, interquartile range; PPM, permanent pacemaker.
*Alternating bundle branch block was considered as a new left bundle branch block in this patient population with pre-existent right bundle branch block.
†Percentage indicates the proportion of patients who received a permanent pacemaker.
‡Follow-up electrocardiograms were missing in 29 patients (23%) at 30 days and in 80 (64%) at 1 year.
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Also, the latest balloon expandable ES-3 THV has a higher
reported PPM rate compared with its predecessor, ES-XT.25
Prevalence of RBBB in this study was similar to what has
been reported in the literature. Our ﬁndings demonstrate a
higher incidence of PPM in patients with pre-existent RBBB
compared to what generally is reported in a random TAVR
population. In patients with pre-existent RBBB treated with
CoreValve in this study, almost half required a PPM as
compared to 20% in the randomized US CoreValve High Risk
Study and 28% in the meta-analysis by Siontis et al.7,26 PPM
rate in patients with ES-XT was 31% and is signiﬁcantly higher
than the 6% in the meta-analysis and 9% in the randomized
PARTNER 2 (Placement of Aortic Transcatheter Valves 2) trial.3
In our study, also with newer generation THVs in patients with
pre-existent RBBB, the PPM rate was consistently higher than
what is reported in high-risk TAVR patients: ES-3 34% versus
10%27 and Lotus 75% versus 27%,9 respectively.
Multivariate analysis conﬁrmed a higher incidence of PPM
with Lotus than with other THV designs. Conversely, ES-XT was
associated with the lowest PPM risk. Interestingly, a higher
BMI before TAVR also predicted PPM implantation, although
the effect was modest. Previous studies reported the impact of
BMI on outcomes post-TAVR, but did not show an enhanced
rate of PPM implantations.4,28 The exact pathophysiology is
unclear. However, BMI may pose particular hurdles from a
procedure execution perspective and maybe result in less-
accurate (and maybe deeper) valve implants. Alternative
access (ie, transsubclavian or transapical access) was asso-
ciated with a lower PPM rate in the univariate model. However,
this effect was absent in the multivariate model, suggesting
the effect of the balloon expandable valves that were used in
the majority (75%) of alternative access procedures.
The high rate of PPM with Lotus could hypothetically be
caused by (1) a higher radial force of the stented frame
compared to other THVs, which potentially forces the native
annulus in a circular shape, and (2) the Lotus frame remains in
contact with the wall of the left ventricular outﬂow tract
throughout the process of foreshortening and locking, which
could be more harmful to the conduction system. Depth of
transcatheter valve implantation is an established predictor
for CoreValve, ES-XT, and ES-3,29–31 in particular with an
implantation depth of more than 6 mm below the native aortic
Figure 2. Forest plot displaying odds ratios (OR) for permanent pacemaker implantation after multivariate analysis. The following variables
were included in the multivariate model: valve type, sex, body mass index (BMI), alternative access, and an interaction term valve
type9alternative access. *Odds ratio per 1 kg/m2 increment of BMI. †An interaction term for the interaction between alternative access and
valve type was included in the model to adjust for the fact that alternative access was not applied with Lotus. ES-3 indicates Edwards Sapien 3;
ES-XT, Edwards Sapien XT; NA, not applicable; PPM, permanent pacemaker.
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valve. Methodology to determine depth of implantation is not
standardized and was not collected in this study. However,
depth of implantation could affect the need for PPM with any
THV and warrants further detailed analysis.
Previous reports suggested the transient nature of TAVR-
induced conduction disorders given that up to half of patients
with new pacemakers post-TAVR were no longer pacemaker
dependent at follow-up.13,32,33 In contrast, our study demon-
strates a paced rhythm in 89% of patients at 1 year in patients
who received a PPM, underscoring a less-resilient conduction
system in these patients. Similarly, patients with pre-existent
RBBB who developed AV3B within 24 hours after the
procedure received a PPM in 91% of the cases, with 1 in 4
receiving the pacemaker more than 4 days post-TAVR,
underscoring the persistence of this conduction disorder. In
aggregate, conduction recovery post-TAVR in patients with
pre-existent RBBB is unlikely, and therefore the decision to
proceed with PPM implantation could be made early after
TAVR to minimize hospital stay.
In our study—involving patients with pre-existent RBBB
and a relatively high rate of PPM implantations—the mortality
rate (7% at 30 days and 18% at 1 year) is on par with recently
published trials and registry data.26,31,34–38 Conﬂicting data
link new conduction disorders in general and PPM implanta-
tion in particular to impaired TAVR-related outcome, including
less improvement in LV function or quality of life, more
rehospitalizations, and increased 1-year mortality.13,39–41
Hypothetically, PPM implantation in patients with RBBB levels
out mortality attributed to the high incidence of—potentially
lethal—total heart blocks.
Limitations
This multicenter study has an observational design and may
suffer from inherent bias in terms of THV selection and
confounders. Depth of implantation—which is known to be
associated with PPM—was not collected in this study. Indeed,
given that balloon expandable devices have less TAVR-related
conduction disorders, operators may already favor this THV
for patients with pre-existent RBBB and avoid mechanically
expanded valves on the other hand. Nonetheless, only THVs
with at least 10 patients in the database were eligible for
further analysis, and the number of events was sufﬁcient to
allow for adequate multivariate analysis to adjust for
confounders. We acknowledge that the Lotus valve is
relatively under-represented in the present study, and there-
fore avoidance of this valve cannot be strongly recommended.
However, we believe that there is a clear signal that this valve
is associated with the highest PPM rate. The decision to
implant a PPM was at the treating physician’s discretion, but
was most often for high-degree AV block and thus conforms
to current international guidelines.17
Conclusion
Postprocedural PPM rate in this cohort of patients with pre-
existent RBBB was consistently higher than described in the
literature for all THVs. PPM rate was highest with Lotus and
lowest with the balloon expandable ES-XT and ES-3. Pace-
maker dependency remained high at both 30-day and 1-year
follow-up.
Sources of Funding
Dr Van Mieghem has received research grants from Claret
Medical, Boston Scientiﬁc, Medtronic, and Edwards Life-
sciences.
Disclosures
Prof Dr De Jaegere is proctor for Boston Scientiﬁc. The
remaining authors have nothing to disclose in relation to this
topic.
References
1. Reinohl J, Kaier K, Reinecke H, Schmoor C, Frankenstein L, Vach W, Cribier A,
Beyersdorf F, Bode C, Zehender M. Effect of availability of transcatheter aortic-
valve replacement on clinical practice. N Engl J Med. 2015;373:2438–2447.
Figure 3. Two-lead electrocardiogram derived from continuous
rhythm monitoring within 24 hours after transcatheter aortic
valve replacement, illustrating the typical cascade from RBBB to a
total atrioventricular block. *Intermittent sinus beats with LBBB.
BBB indicates bundle branch block; LBBB, left bundle branch
block; RBBB, right bundle branch block.
DOI: 10.1161/JAHA.116.005028 Journal of the American Heart Association 6
TAVR in RBBB van Gils et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 18, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
2. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM,
Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard
AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN,
Wang D, Pocock S; Investigators PT. Transcatheter aortic-valve implantation
for aortic stenosis in patients who cannot undergo surgery. N Engl J Med.
2010;363:1597–1607.
3. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani
VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD,
Kapadia S, Dewey T, Babaliaros V, Szeto WY, Williams MR, Kereiakes D,
Zajarias A, Greason KL, Whisenant BK, Hodson RW, Moses JW, Trento A, Brown
DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA, Anderson WN, Alu MC, Webb JG;
Investigators P. Transcatheter or surgical aortic-valve replacement in
intermediate-risk patients. N Engl J Med. 2016;374:1609–1620.
4. Yamamoto M, Mouillet G, Oguri A, Gilard M, Laskar M, Eltchaninoff H,
Fajadet J, Iung B, Donzeau-Gouge P, Leprince P, Leuguerrier A, Prat A, Lievre
M, Chevreul K, Dubois-Rande JL, Teiger E; Investigators FR. Effect of body
mass index on 30- and 365-day complication and survival rates of
transcatheter aortic valve implantation (from the French Aortic National
Corevalve and Edwards 2 [FRANCE 2] Registry). Am J Cardiol.
2013;112:1932–1937.
5. van der Boon RM, Nuis RJ, Van Mieghem NM, Jordaens L, Rodes-Cabau J, van
Domburg RT, Serruys PW, Anderson RH, de Jaegere PP. New conduction
abnormalities after TAVI–frequency and causes. Nat Rev Cardiol. 2012;9:454–
463.
6. Nuis RJ, Van Mieghem NM, Schultz CJ, Tzikas A, Van der Boon RM, Maugenest
AM, Cheng J, Piazza N, van Domburg RT, Serruys PW, de Jaegere PP. Timing
and potential mechanisms of new conduction abnormalities during the
implantation of the Medtronic CoreValve System in patients with aortic
stenosis. Eur Heart J. 2011;32:2067–2074.
7. Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, Wenaweser P,
Windecker S. Predictors of permanent pacemaker implantation in patients
with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll
Cardiol. 2014;64:129–140.
8. Houthuizen P, van der Boon RM, Urena M, Van Mieghem N, Brueren GB, Poels
TT, Van Garsse LA, Rodes-Cabau J, Prinzen FW, de Jaegere P. Occurrence, fate
and consequences of ventricular conduction abnormalities after transcatheter
aortic valve implantation. EuroIntervention. 2014;9:1142–1150.
9. Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, Tchetche D,
Manoharan G, Blackman DJ, Rioufol G, Hildick-Smith D, Whitbourn RJ, Lefevre
T, Lange R, Muller R, Redwood S, Allocco DJ, Dawkins KD. Transcatheter aortic
valve replacement for severe symptomatic aortic stenosis using a reposition-
able valve system: 30-day primary endpoint results from the REPRISE II study.
J Am Coll Cardiol. 2014;64:1339–1348.
10. Schofer J, Colombo A, Klugmann S, Fajadet J, DeMarco F, Tchetche D, Maisano
F, Bruschi G, Latib A, Bijuklic K, Weissman N, Low R, Thomas M, Young C,
Redwood S, Mullen M, Yap J, Grube E, Nickenig G, Sinning JM, Hauptmann KE,
Friedrich I, Lauterbach M, Schmoeckel M, Davidson C, Lefevre T. Prospective
multicenter evaluation of the direct ﬂow medical transcatheter aortic valve. J
Am Coll Cardiol. 2014;63:763–768.
11. Willson AB, Rodes-Cabau J, Wood DA, Leipsic J, Cheung A, Toggweiler S, Binder
RK, Freeman M, DeLarochelliere R, Moss R, Nombela-Franco L, Dumont E,
Szummer K, Fontana GP, Makkar R, Webb JG. Transcatheter aortic valve
replacement with the St. Jude Medical Portico valve: ﬁrst-in-human experi-
ence. J Am Coll Cardiol. 2012;60:581–586.
12. Rivard L, Schram G, Asgar A, Khairy P, Andrade JG, Bonan R, Dubuc M, Guerra
PG, Ibrahim R, Macle L, Roy D, Talajic M, Dyrda K, Shohoudi A, le Polain de
Waroux JB, Thibault B. Electrocardiographic and electrophysiological predic-
tors of atrioventricular block after transcatheter aortic valve replacement.
Heart Rhythm. 2015;12:321–329.
13. Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, El-Chami MF,
Herrmann HC, Mack M, Makkar RR, Miller DC, Pichard A, Tuzcu EM, Szeto
WY, Webb JG, Moses JW, Smith CR, Williams MR, Leon MB, Kodali SK; Ofﬁce
PP. Predictors and clinical outcomes of permanent pacemaker implantation
after transcatheter aortic valve replacement: the PARTNER (placement of
aortic transcatheter valves) trial and registry. JACC Cardiovasc Interv.
2015;8:60–69.
14. Khawaja MZ, Rajani R, Cook A, Khavandi A, Moynagh A, Chowdhary S, Spence
MS, Brown S, Khan SQ, Walker N, Trivedi U, Hutchinson N, De Belder AJ, Moat
N, Blackman DJ, Levy RD, Manoharan G, Roberts D, Khogali SS, Crean P,
Brecker SJ, Baumbach A, Mullen M, Laborde JC, Hildick-Smith D. Permanent
pacemaker insertion after CoreValve transcatheter aortic valve implantation:
incidence and contributing factors (the UK CoreValve Collaborative). Circula-
tion. 2011;123:951–960.
15. van der Boon RM, Houthuizen P, Urena M, Poels TT, van Mieghem NM, Brueren
GR, Altintas S, Nuis RJ, Serruys PW, van Garsse LA, van Domburg RT, Cabau JR,
de Jaegere PP, Prinzen FW. Trends in the occurrence of new conduction
abnormalities after transcatheter aortic valve implantation. Catheter Cardio-
vasc Interv. 2015;85:144–152.
16. Saia F, Lemos PA, Bordoni B, Cervi E, Boriani G, Ciuca C, Taglieri N, Mariani J Jr,
Filho RK, Marzocchi A. Transcatheter aortic valve implantation with a self-
expanding nitinol bioprosthesis: prediction of the need for permanent
pacemaker using simple baseline and procedural characteristics. Catheter
Cardiovasc Interv. 2012;79:712–719.
17. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt
OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq
C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE; Guidelines ESCCfP,
Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton
C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P,
Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes
PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R,
Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D,
Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D,
Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T,
Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera
M, Van Gelder IC, Wilson CM. 2013 ESC guidelines on cardiac pacing and
cardiac resynchronization therapy: the Task Force on cardiac pacing and
resynchronization therapy of the European Society of Cardiology (ESC).
Developed in collaboration with the European Heart Rhythm Association
(EHRA). Eur Heart J. 2013;34:2281–2329.
18. Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone
EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW,
Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker
S, Serruys PW, Leon MB. Updated standardized endpoint deﬁnitions for
transcatheter aortic valve implantation: the Valve Academic Research
Consortium-2 consensus document. Eur Heart J. 2012;33:2403–2418.
19. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study
of the number of events per variable in logistic regression analysis. J Clin
Epidemiol. 1996;49:1373–1379.
20. Bussink BE, Holst AG, Jespersen L, Deckers JW, Jensen GB, Prescott E. Right
bundle branch block: prevalence, risk factors, and outcome in the general
population: results from the Copenhagen City Heart Study. Eur Heart J.
2013;34:138–146.
21. Haataja P, Nikus K, Kahonen M, Huhtala H, Nieminen T, Jula A, Reunanen A,
Salomaa V, Sclarovsky S, Nieminen MS, Eskola M. Prevalence of ventricular
conduction blocks in the resting electrocardiogram in a general population:
the Health 2000 Survey. Int J Cardiol. 2013;167:1953–1960.
22. Van Mieghem NM, Head SJ, de Jong W, van Domburg RT, Serruys PW, de
Jaegere PP, Jordaens L, Takkenberg JJ, Bogers AJ, Kappetein AP. Persistent
annual permanent pacemaker implantation rate after surgical aortic valve
replacement in patients with severe aortic stenosis. Ann Thorac Surg.
2012;94:1143–1149.
23. Meredith IT, Worthley SG, Whitbourn RJ, Antonis P, Montarello JK, Newcomb
AE, Lockwood S, Haratani N, Allocco DJ, Dawkins KD. Transfemoral aortic
valve replacement with the repositionable Lotus Valve System in high surgical
risk patients: the REPRISE I study. EuroIntervention. 2014;9:1264–1270.
24. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS,
Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page
RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs
AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP,
Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW,
Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW;
American College of Cardiology/American Heart Association Task Force on
Practice G, American Association for Thoracic S, Society of Thoracic S. ACC/
AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm
abnormalities: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (writing committee to revise the
ACC/AHA/NASPE 2002 guideline update for implantation of cardiac
pacemakers and antiarrhythmia devices) developed in collaboration with the
American Association for Thoracic Surgery and Society of Thoracic Surgeons. J
Am Coll Cardiol. 2008;51:e1–e62.
25. Toggweiler S, Gurvitch R, Leipsic J, Wood DA, Willson AB, Binder RK, Cheung A,
Ye J, Webb JG. Percutaneous aortic valve replacement: vascular outcomes with
a fully percutaneous procedure. J Am Coll Cardiol. 2012;59:113–118.
26. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with
a self-expanding prosthesis. N Engl J Med. 2014;371:967–968.
27. Nijhoff F, Abawi M, Agostoni P, Ramjankhan FZ, Doevendans PA, Stella PR.
Transcatheter aortic valve implantation with the new balloon-expandable
Sapien 3 versus Sapien XT valve system: a propensity score-matched single-
center comparison. Circ Cardiovasc Interv. 2015;8:e002408.
28. Abramowitz Y, Chakravarty T, Jilaihawi H, Cox J, Sharma RP, Mangat G,
Nakamura M, Cheng W, Makkar RR. Impact of body mass index on the
outcomes following transcatheter aortic valve implantation. Catheter Cardio-
vasc Interv. 2016;88:127–134.
29. Binder RK, Webb JG, Toggweiler S, Freeman M, Barbanti M, Willson AB,
Alhassan D, Hague CJ, Wood DA, Leipsic J. Impact of post-implant SAPIEN XT
geometry and position on conduction disturbances, hemodynamic
DOI: 10.1161/JAHA.116.005028 Journal of the American Heart Association 7
TAVR in RBBB van Gils et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 18, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
performance, and paravalvular regurgitation. JACC Cardiovasc Interv.
2013;6:462–468.
30. Husser O, Pellegrini C, Kessler T, Burgdorf C, Thaller H, Mayr NP, Kasel AM,
Kastrati A, Schunkert H, Hengstenberg C. Predictors of permanent pacemaker
implantations and new-onset conduction abnormalities with the SAPIEN 3
balloon-expandable transcatheter heart valve. JACC Cardiovasc Interv.
2016;9:244–254.
31. Petronio AS, Sinning JM, Van Mieghem N, Zucchelli G, Nickenig G, Bekeredjian
R, Bosmans J, Bedogni F, Branny M, Stangl K, Kovac J, Schiltgen M, Kraus S, de
Jaegere P. Optimal implantation depth and adherence to guidelines on
permanent pacing to improve the results of transcatheter aortic valve
replacement with the Medtronic CoreValve System: the CoreValve prospec-
tive, international, post-market ADVANCE-II study. JACC Cardiovasc Interv.
2015;8:837–846.
32. Roten L, Stortecky S, Scarcia F, Kadner A, Tanner H, Delacretaz E, Meier B,
Windecker S, Carrel T, Wenaweser P. Atrioventricular conduction after
transcatheter aortic valve implantation and surgical aortic valve replacement.
J Cardiovasc Electrophysiol. 2012;23:1115–1122.
33. van der Boon RM, Van Mieghem NM, Theuns DA, Nuis RJ, Nauta ST, Serruys
PW, Jordaens L, van Domburg RT, de Jaegere PP. Pacemaker dependency after
transcatheter aortic valve implantation with the self-expanding Medtronic
CoreValve System. Int J Cardiol. 2013;168:1269–1273.
34. Linke A, Wenaweser P, Gerckens U, Tamburino C, Bosmans J, Bleiziffer S,
Blackman D, Schafer U, Muller R, Sievert H, Sondergaard L, Klugmann S,
Hoffmann R, Tchetche D, Colombo A, Legrand VM, Bedogni F, lePrince P,
Schuler G, Mazzitelli D, Eftychiou C, Frerker C, Boekstegers P, Windecker S,
Mohr FW, Woitek F, Lange R, Bauernschmitt R, Brecker S; Investigators As.
Treatment of aortic stenosis with a self-expanding transcatheter valve: the
International Multi-centre ADVANCE Study. Eur Heart J. 2014;35:2672–2684.
35. Schymik G, Lefevre T, Bartorelli AL, Rubino P, Treede H, Walther T, Baumgartner
H, Windecker S, Wendler O, Urban P, Mandinov L, Thomas M, Vahanian A.
European experience with the second-generation Edwards SAPIEN XT tran-
scatheter heart valve in patients with severe aortic stenosis: 1-year outcomes
from the SOURCE XT Registry. JACC Cardiovasc Interv. 2015;8:657–669.
36. Holmes DR Jr, Nishimura RA, Grover FL, Brindis RG, Carroll JD, Edwards FH,
Peterson ED, Rumsfeld JS, Shahian DM, Thourani VH, Tuzcu EM, Vemulapalli S,
Hewitt K, Michaels J, Fitzgerald S, Mack MJ; Registry SAT. Annual outcomes
with transcatheter valve therapy: from the STS/ACC TVT Registry. J Am Coll
Cardiol. 2015;66:2813–2823.
37. Hamm CW, Mollmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, Cremer J,
Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Bohm
M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S,
Welz A, Mohr FW; Board GA-E. The german aortic valve registry (GARY): in-
hospital outcome. Eur Heart J. 2014;35:1588–1598.
38. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, Chevreul K, Fajadet J,
Leprince P, Leguerrier A, Lievre M, Prat A, Teiger E, Lefevre T, Himbert D,
Tchetche D, Carrie D, Albat B, Cribier A, Rioufol G, Sudre A, Blanchard D, Collet
F, Dos Santos P, Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J,
Le Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau X, Ohlmann
P, Doisy V, Grollier G, Gommeaux A, Claudel JP, Bourlon F, Bertrand B, Van
Belle E, Laskar M; Investigators F. Registry of transcatheter aortic-valve
implantation in high-risk patients. N Engl J Med. 2012;366:1705–1715.
39. Nazif TM, Williams MR, Hahn RT, Kapadia S, Babaliaros V, Rodes-Cabau J,
Szeto WY, Jilaihawi H, Fearon WF, Dvir D, Dewey TM, Makkar RR, Xu K, Dizon
JM, Smith CR, Leon MB, Kodali SK. Clinical implications of new-onset left
bundle branch block after transcatheter aortic valve replacement: analysis of
the partner experience. Eur Heart J. 2014;35:1599–1607.
40. Houthuizen P, Van Garsse LA, Poels TT, de Jaegere P, van der Boon RM,
Swinkels BM, Ten Berg JM, van der Kley F, Schalij MJ, Baan J Jr, Cocchieri R,
Brueren GR, van Straten AH, den Heijer P, Bentala M, van Ommen V, Kluin J,
Stella PR, Prins MH, Maessen JG, Prinzen FW. Left bundle-branch block
induced by transcatheter aortic valve implantation increases risk of death.
Circulation. 2012;126:720–728.
41. Testa L, Latib A, De Marco F, De Carlo M, Agniﬁli M, Latini RA, Petronio AS,
Ettori F, Poli A, De Servi S, Ramondo A, Napodano M, Klugmann S, Ussia GP,
Tamburino C, Brambilla N, Colombo A, Bedogni F. Clinical impact of persistent
left bundle-branch block after transcatheter aortic valve implantation with
CoreValve Revalving System. Circulation. 2013;127:1300–1307.
DOI: 10.1161/JAHA.116.005028 Journal of the American Heart Association 8
TAVR in RBBB van Gils et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on A
pril 18, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
  
 
 
 
SUPPLEMENTAL MATERIAL 
  
 by guest on A
pril 18, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Table S1. Predictors for permanent pacemaker implantation. 
 
 Univariate OR [95% CI] P-Value 
Type of THV   
Lotus vs. CoreValve 3.50 [1.20-10.20] .022 
Lotus vs. ES-XT 6.30 [2.14-18.55] .001 
Lotus vs. ES-3 5.73 [1.65-19.94] .006 
CoreValve vs. ES-XT 1.80 [1.08-3.00] .024 
CoreValve vs. ES-3 1.64 [0.73-3.67] . 232 
ES-XT   vs. ES-3 0.91 [0.40-2.07] .820 
Patient characteristics   
Alternative access 0.32 [0.15-0.69] .004 
Baseline atrial fibrillation 0.79 [0.44-1.42] .429 
Body mass index* 1.08 [1.02-1.14] .006 
Female sex 1.49 [0.93-2.39] .098 
Medication Amiodarone 0.87 [0.43-1.75] .690 
Medication Digitalis 0.86 [0.25-3.00] .813 
NYHA - class ≥ III 0.92 [0.54-1.58] .765 
Prior SAVR 0.40 [0.08-1.95] .256 
 
Results from univariate logistic regression analysis. Variables in italic were included in the multivariate 
analysis. *Odds ratio per 1 kg/m2 increment of body mass index. Abbreviations: CI = confidence 
interval; ES-3 = Edwards sapien valve 3; ES-XT = Edwards Sapien XT; NYHA = New York Heart 
Association; SAVR = surgical aortic valve replacement; THV = transcatheter heart valve.  
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Table S2. Predictors for new total atrioventricular block <24h. 
 
 Univariate OR  
(95% CI) 
P-Value Multivariate OR  
(95% CI) 
P-Value 
Type of THV     
Lotus vs. CoreValve 3.43 (1.22-9.63) .019 3.80 (1.25-11.52) .018 
Lotus vs. ES-XT 5.92 (2.06-16-99) .001 6.01 (1.93-18.67) .002 
Lotus vs. ES-3 3.47 (0.99-12.09) .051 3.88 (1.02-14.82) .047 
CoreValve vs. ES-XT 1.73 (0.99-3.00) .053 1.58 (0.88-2.85) .128 
CoreValve vs. ES-3 1.01 (0.42-2.41) .981   
ES-XT   vs. ES-3 0.59 (0.24-1.43) .240 0.17 (0.05-0.52) .002 
Patient characteristics     
Alternative access 0.51 (0.21-1.23) .133 0.48 (0.13-1.81) .281 
Baseline atrial fibrillation 1.00 (0.53-1.86) .987   
Body mass index 1.04 (0.99 -1.10) .126 1.04 (0.98-1.10) .218 
Female sex 1.39 (0.84-2.29) .200 1.30 (0.77-2.20) .326 
Prior surgical aortic  
valve replacement 
0.89 (0.22-3.63) .868   
 
Results from uni- and multivariate logistic regression for new onset third degree atrioventricular block 
within 24 hours. Variables in italic were included in multivariate regression. Abbreviations: CI = 
confidence interval; ES-XT = Edwards Sapien XT; ES-3 = Edwards Sapien 3; OR = Odds Ratio; THV 
= transcatheter heart valve. 
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